Loading...
Tocilizumab for the treatment of severe coronavirus disease 2019
Tocilizumab, an interleukin‐6 inhibitor, may ameliorate the inflammatory manifestations associated with severe coronavirus disease 2019 (COVID‐19) and thus improve clinical outcomes. This was a retrospective review of patients with laboratory‐confirmed severe COVID‐19 who received tocilizumab and co...
Saved in:
| Published in: | J Med Virol |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
John Wiley and Sons Inc.
2020
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7267594/ https://ncbi.nlm.nih.gov/pubmed/32369191 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jmv.25964 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|